Sinovac Biotech Ltd
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza;… Read more
Sinovac Biotech Ltd (SVA) - Net Assets
Latest net assets as of June 2024: $11.51 Billion USD
Based on the latest financial reports, Sinovac Biotech Ltd (SVA) has net assets worth $11.51 Billion USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.90 Billion) and total liabilities ($1.39 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.51 Billion |
| % of Total Assets | 89.22% |
| Annual Growth Rate | 67.77% |
| 5-Year Change | 3313.67% |
| 10-Year Change | 8383.11% |
| Growth Volatility | 2339.04 |
Sinovac Biotech Ltd - Net Assets Trend (1998–2023)
This chart illustrates how Sinovac Biotech Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sinovac Biotech Ltd (1998–2023)
The table below shows the annual net assets of Sinovac Biotech Ltd from 1998 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $12.02 Billion | -5.43% |
| 2022-12-31 | $12.71 Billion | -8.38% |
| 2021-12-31 | $13.88 Billion | +1138.79% |
| 2020-12-31 | $1.12 Billion | +218.04% |
| 2019-12-31 | $352.19 Million | +20.64% |
| 2018-12-31 | $291.93 Million | +125.14% |
| 2017-12-31 | $129.67 Million | 0.00% |
| 2016-12-31 | $129.67 Million | -5.01% |
| 2015-12-31 | $136.50 Million | -3.68% |
| 2014-12-31 | $141.73 Million | -1.33% |
| 2013-12-31 | $143.64 Million | +10.97% |
| 2012-12-31 | $129.44 Million | -10.92% |
| 2011-12-31 | $145.30 Million | -1.66% |
| 2010-12-31 | $147.76 Million | +74.93% |
| 2009-12-31 | $84.47 Million | +57.48% |
| 2008-12-31 | $53.64 Million | +63.02% |
| 2007-12-31 | $32.90 Million | +54.41% |
| 2006-12-31 | $21.31 Million | +29.07% |
| 2005-12-31 | $16.51 Million | +6.08% |
| 2004-12-31 | $15.56 Million | +42.94% |
| 2003-12-31 | $10.89 Million | +10848.47% |
| 2002-12-31 | $99.44K | +114.56% |
| 2001-12-31 | $-682.96K | 0.00% |
| 2000-12-31 | $-682.96K | -2454.45% |
| 1998-12-31 | $29.01K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sinovac Biotech Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 711852249300.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $7.12 Billion | 81.73% |
| Common Stock | $100.00K | 0.00% |
| Other Comprehensive Income | $1.05 Billion | 12.05% |
| Other Components | $541.27 Million | 6.21% |
| Total Equity | $8.71 Billion | 100.00% |
Sinovac Biotech Ltd Competitors by Market Cap
The table below lists competitors of Sinovac Biotech Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mensch und Maschine Software SE
PINK:MSHHF
|
$385.09 Million |
|
Wavestone S.A.
PA:WAVE
|
$385.16 Million |
|
UNIV. STAINLESS+AL.DL-01
F:US6
|
$385.20 Million |
|
Beijing Electronic Zone Investment and Development Group Co Ltd
SHG:600658
|
$385.30 Million |
|
LiJiang YuLong Tourism Co Ltd
SHE:002033
|
$384.99 Million |
|
OSK Holdings Bhd
KLSE:5053
|
$384.91 Million |
|
Ironwood Pharmaceuticals Inc
NASDAQ:IRWD
|
$384.72 Million |
|
Grid Dynamics Holdings Inc
NASDAQ:GDYN
|
$384.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sinovac Biotech Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 8,921,421,000 to 8,709,418,000, a change of -212,003,000 (-2.4%).
- Net loss of 99,918,000 reduced equity.
- Dividend payments of 328,080,000 reduced retained earnings.
- New share issuances of 676,000 increased equity.
- Other comprehensive income decreased equity by 105,208,000.
- Other factors increased equity by 320,527,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-99.92 Million | -1.15% |
| Dividends Paid | $328.08 Million | -3.77% |
| Share Issuances | $676.00K | +0.01% |
| Other Comprehensive Income | $-105.21 Million | -1.21% |
| Other Changes | $320.53 Million | +3.68% |
| Total Change | $- | -2.38% |
Book Value vs Market Value Analysis
This analysis compares Sinovac Biotech Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1315.99x to 0.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $0.00 | $6.47 | x |
| 2000-12-31 | $-0.10 | $6.47 | x |
| 2001-12-31 | $-0.10 | $6.47 | x |
| 2002-12-31 | $0.01 | $6.47 | x |
| 2003-12-31 | $0.17 | $6.47 | x |
| 2004-12-31 | $0.38 | $6.47 | x |
| 2005-12-31 | $0.40 | $6.47 | x |
| 2006-12-31 | $0.50 | $6.47 | x |
| 2007-12-31 | $0.74 | $6.47 | x |
| 2008-12-31 | $1.13 | $6.47 | x |
| 2009-12-31 | $1.64 | $6.47 | x |
| 2010-12-31 | $2.38 | $6.47 | x |
| 2011-12-31 | $2.38 | $6.47 | x |
| 2012-12-31 | $2.14 | $6.47 | x |
| 2013-12-31 | $2.31 | $6.47 | x |
| 2014-12-31 | $2.27 | $6.47 | x |
| 2015-12-31 | $2.16 | $6.47 | x |
| 2016-12-31 | $2.03 | $6.47 | x |
| 2017-12-31 | $2.03 | $6.47 | x |
| 2018-12-31 | $3.90 | $6.47 | x |
| 2019-12-31 | $2.68 | $6.47 | x |
| 2020-12-31 | $6.57 | $6.47 | x |
| 2021-12-31 | $81.82 | $6.47 | x |
| 2022-12-31 | $78.14 | $6.47 | x |
| 2023-12-31 | $87.44 | $6.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sinovac Biotech Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.29%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.57x
- Recent ROE (-1.15%) is above the historical average (-3.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -22.38% | 0.00% | 0.00x | 1.16x | $-9.39K |
| 2000 | 0.00% | -150.93% | 1.18x | 0.00x | $-412.39K |
| 2001 | 0.00% | -152.15% | 1.18x | 0.00x | $-416.30K |
| 2002 | -175.19% | -33.55% | 2.20x | 2.38x | $-184.15K |
| 2003 | -14.18% | -30.73% | 0.19x | 2.42x | $-1.49 Million |
| 2004 | -37.52% | -72.31% | 0.29x | 1.80x | $-5.91 Million |
| 2005 | -33.97% | -68.08% | 0.28x | 1.81x | $-5.69 Million |
| 2006 | -3.62% | -4.53% | 0.41x | 1.92x | $-2.62 Million |
| 2007 | 25.50% | 22.81% | 0.58x | 1.91x | $4.65 Million |
| 2008 | 16.74% | 17.23% | 0.60x | 1.62x | $3.23 Million |
| 2009 | 28.25% | 23.70% | 0.58x | 2.06x | $12.89 Million |
| 2010 | -6.73% | -25.47% | 0.16x | 1.70x | $-21.15 Million |
| 2011 | -0.65% | -1.48% | 0.26x | 1.66x | $-13.84 Million |
| 2012 | -12.62% | -30.18% | 0.24x | 1.77x | $-26.63 Million |
| 2013 | 5.78% | 10.37% | 0.30x | 1.87x | $-5.43 Million |
| 2014 | -1.20% | -2.41% | 0.26x | 1.88x | $-14.17 Million |
| 2015 | -1.16% | -2.10% | 0.33x | 1.67x | $-13.58 Million |
| 2016 | -0.51% | -0.82% | 0.34x | 1.83x | $-12.17 Million |
| 2017 | 22.29% | 14.80% | 0.82x | 1.83x | $14.23 Million |
| 2018 | 8.59% | 9.48% | 0.62x | 1.46x | $-3.56 Million |
| 2019 | 15.28% | 18.26% | 0.54x | 1.54x | $15.53 Million |
| 2020 | 14.79% | 21.61% | 0.27x | 2.55x | $35.72 Million |
| 2021 | 90.78% | 43.70% | 1.16x | 1.80x | $7.53 Billion |
| 2022 | 1.28% | 7.63% | 0.11x | 1.58x | $-778.28 Million |
| 2023 | -1.15% | -22.29% | 0.03x | 1.57x | $-970.86 Million |
Industry Comparison
This section compares Sinovac Biotech Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sinovac Biotech Ltd (SVA) | $11.51 Billion | -22.38% | 0.12x | $385.02 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |